Hermetica Superfood Encyclopedia
The Short Answer
Chasmanthera dependens contains protoberberine and aporphine alkaloids—including jatrorrhizine, palmatine, tetrahydropalmatine, and glaucine—that suppress inflammatory mediators such as COX-2, TNF-α, and PGE-2 through alkaloid-mediated modulation of the arachidonic acid cascade. Preclinical studies demonstrate that oral methanol leaf extract at 100–400 mg/kg produces dose-dependent inhibition of carrageenan-induced paw edema and acetic acid–induced writhing in rodents, with in vitro potency in some polyherbal gel formulations exceeding that of diclofenac gel against COX-2 and TNF-α; no human clinical data exist.
CategoryHerb
GroupAfrican
Evidence LevelPreliminary
Primary KeywordChasmanthera dependens benefits
Climbing Blueflower — botanical close-up
Health Benefits
**Anti-Inflammatory Activity**
Methanol leaf extracts inhibit COX-2, TNF-α, IL-10, and PGE-2 in a dose-dependent manner in vitro, with efficacy comparable to or exceeding diclofenac gel in polyherbal formulations; the protoberberine alkaloids jatrorrhizine and palmatine are principal contributors.
**Analgesic Effects**
Rodent models demonstrate significant reduction of acetic acid–induced writhing and both early (neurogenic) and late (inflammatory) phases of formalin-induced paw licking at 100–400 mg/kg oral doses, consistent with peripheral and central analgesic pathways modulated by tetrahydropalmatine and related alkaloids.
**Antipyretic Potential**
Traditional use across Igbo and Yoruba communities of Nigeria includes fever management, plausibly supported by the anti-inflammatory alkaloid profile that suppresses prostaglandin synthesis upstream of the hypothalamic thermoregulatory axis.
**Antimicrobial Properties**
The isolated furanoditerpenoid epoxycolumbin exhibits antimicrobial potential against select bacterial and fungal species in preliminary screening, complementing the broad traditional use of stem and leaf preparations for infectious conditions including malaria-associated febrile illness.
**Topical Anti-Inflammatory Application**
Polyherbal carbopol 940 gels (1%) incorporating Chasmanthera dependens leaf extract at varied ratios with Chenopodium ambrosioides demonstrated favorable physicochemical properties (pH 4.5–5.2, viscosity 4.3–4.7 Pa·s, good spreadability) and significant in vitro inhibition of inflammatory biomarkers, supporting topical delivery as a viable formulation strategy.
**Antioxidant Contribution**
The presence of tannins, flavonoids, and phenolic compounds in ethanolic leaf extracts provides a basis for free radical scavenging activity, which may synergistically enhance the anti-inflammatory effects by reducing oxidative stress–driven NF-κB activation.
**Traditional Antimalarial Use**
In West African ethnomedicine, particularly among Igbo and Yoruba practitioners, the plant is used in polyherbal formulations targeting malaria, with alkaloids such as palmatine sharing structural and mechanistic homology with established antimalarial protoberberines, though direct antimalarial efficacy for this species remains unconfirmed by controlled studies.
Origin & History
Natural habitat
Chasmanthera dependens is a twining climbing plant native to tropical West and Central Africa, distributed widely across Nigeria, Ghana, Cameroon, and neighboring countries in lowland forest edges, secondary bush, and riverine margins. It thrives in humid tropical conditions with rich, well-drained soils and is commonly found entwining shrubs and forest understory trees. The plant is not commercially cultivated but is harvested from wild stands by traditional healers, who use the stems and leaves as primary medicinal materials.
“Chasmanthera dependens occupies a significant place in the traditional medicine systems of West African peoples, particularly the Igbo and Yoruba of Nigeria, where the plant has been used for generations to manage pain, inflammatory conditions, febrile illness, and malaria-associated symptoms. The plant is typically employed in polyherbal formulations—reflecting the broader African ethnobotanical tradition of combining complementary plant materials—with healers selecting stems and leaves as the primary medicinal organs based on their observable resinous and bitter character, indicators associated with potency in local pharmacognostic knowledge. Preparation methods including hot-water decoctions of stems and macerated leaf preparations are passed orally through apprenticeship systems, and the plant's common name references both its climbing growth habit and the blue-toned flowers that distinguish it in the field. While formal historical documentation predating modern ethnobotanical surveys is limited, the consistency of its uses across geographically separated ethnic groups in West and Central Africa suggests a deep and independently validated traditional pharmacological legacy.”Traditional Medicine
Scientific Research
The evidence base for Chasmanthera dependens is limited exclusively to in vitro cell-free assays and small-scale rodent pharmacology studies; no randomized controlled trials, human pharmacokinetic studies, or systematic reviews exist in the indexed literature. Preclinical anti-inflammatory studies employed oral methanol leaf extract at 100–400 mg/kg in rat carrageenan paw edema and cotton pellet granuloma models, reporting dose-related inhibition without specifying sample sizes, variance, or standardized effect sizes, which substantially limits interpretability. In vitro polyherbal gel studies demonstrated inhibition of COX-2, TNF-α, IL-10, and PGE-2 with some formulations outperforming diclofenac gel, but these findings lack quantitative reporting of IC50 values or confidence intervals. Phytochemical characterization studies provide robust qualitative alkaloid profiling, including isolation of epoxycolumbin, but the absence of quantitative concentration data and bioavailability studies leaves the translational relevance of these findings highly uncertain.
Preparation & Dosage
Traditional preparation
**Oral Methanol/Ethanol Extract (Preclinical Reference Dose)**
100–400 mg/kg body weight in rodents; no validated human equivalent dose established; direct extrapolation is not recommended without clinical safety data
**Ethanolic Leaf Extract (Phytochemical Preparation)**
Dried leaves extracted with 70–95% ethanol using maceration or Soxhlet apparatus; used in laboratory screening and traditional decoction analogs; no standardization percentage defined.
**Stem Decoction (Traditional West African Preparation)**
Stem segments boiled in water and taken orally or applied topically by traditional healers in Nigeria for pain and fever; no standardized volume, concentration, or frequency is documented in the literature.
**Topical Polyherbal Gel (Experimental Form)**
1% carbopol 940 gel base incorporating leaf extract combined with Chenopodium ambrosioides at variable ratios; pH 4.5–5.2, viscosity 4.3–4.7 Pa·s; not commercially available; formulation tested in vitro only.
**Timing and Frequency**
No clinical data exist to guide dosing frequency, duration of use, or optimal timing relative to meals; traditional use patterns are not systematically documented.
Nutritional Profile
Chasmanthera dependens is not a food ingredient and lacks a conventional macronutrient or micronutrient profile in nutritional databases. Phytochemical screening of ethanolic leaf extracts qualitatively confirms the presence of alkaloids (including quaternary protoberberines: jatrorrhizine, columbamine, pseudocolumbamine, magnoflorine, palmatine; and tertiary aporphines: tetrahydropalmatine, liriodenine, lysicamine, oxoglaucine, glaucine, anonaine, nornuciferine, norglaucine, O,O-dimethylcorytuberine), tannins, saponins, flavonoids, phenolic compounds, anthraquinones, and steroids. Cardiac glycosides, phlobatannins, and terpenoids are absent from leaf extracts based on standard phytochemical screening. No quantitative concentrations (mg/g dry weight) have been published for any compound, and bioavailability data—including oral absorption, first-pass metabolism, and protein binding—are entirely absent from the scientific literature for this species.
How It Works
Mechanism of Action
The primary anti-inflammatory mechanism involves alkaloid-mediated suppression of the arachidonic acid cascade: protoberberine alkaloids including jatrorrhizine, palmatine, and columbamine inhibit cyclooxygenase-2 (COX-2) enzyme activity, reducing prostaglandin E2 (PGE-2) biosynthesis and thereby attenuating peripheral sensitization of nociceptors. Concurrently, downregulation of pro-inflammatory cytokines TNF-α and modulation of IL-10 suggest interference with NF-κB–driven transcriptional programs, though direct NF-κB binding studies have not been conducted for this species. The tertiary alkaloid tetrahydropalmatine, a known dopamine D1/D2 and GABA receptor modulator in related Menispermaceae species, likely contributes to central analgesic effects observed in the formalin and writhing assays, possibly through opioid-independent pathways. The furanoditerpenoid epoxycolumbin may contribute to antimicrobial activity through membrane disruption mechanisms analogous to other terpenoid scaffolds, though its specific molecular target in Chasmanthera dependens has not been elucidated.
Clinical Evidence
No human clinical trials have been conducted on Chasmanthera dependens in any form or indication. Available preclinical evidence from rodent models supports analgesic and anti-inflammatory activity at oral doses of 100–400 mg/kg methanol leaf extract, encompassing outcomes of paw edema volume, writhing frequency, and formalin response phases, but effect sizes, confidence intervals, and sample sizes are uniformly unreported across published sources. In vitro studies using polyherbal topical gel formulations provide mechanistic plausibility for COX-2 and cytokine suppression but cannot substitute for clinical efficacy data. Overall confidence in therapeutic claims remains very low, and the ingredient should be regarded as a preliminary ethnobotanical candidate requiring rigorous Phase I safety and pharmacokinetic investigation before any clinical recommendation can be made.
Safety & Interactions
No formal human safety studies, toxicological assessments, or adverse event reporting exists for Chasmanthera dependens, making its safety profile in humans entirely unknown; use in any supplemental or therapeutic context should be approached with caution until Phase I data are available. Preclinical rodent studies employing oral doses of 100–400 mg/kg methanol extract reported no overt toxicity or mortality, but the absence of systematic acute and subchronic toxicity studies (e.g., LD50 determination, organ histopathology) renders even preclinical safety characterization incomplete. The protoberberine alkaloids present—particularly palmatine and jatrorrhizine—are known in other species to inhibit CYP3A4 and P-glycoprotein, suggesting potential for pharmacokinetic interactions with drugs metabolized by these pathways, including immunosuppressants, antiretrovirals, and certain antifungals, though this has not been specifically investigated for this plant. Pregnancy and lactation contraindications cannot be assessed due to complete absence of reproductive toxicology data; alkaloid-containing plants are generally avoided in pregnancy as a precautionary measure.
Synergy Stack
Hermetica Formulation Heuristic
Also Known As
Chasmanthera dependensClimbing BlueflowerMenispermaceae climbing vineIgbo pain plantNigerian analgesic herb
Frequently Asked Questions
What is Climbing Blueflower (Chasmanthera dependens) used for traditionally?
In West African traditional medicine, particularly among the Igbo and Yoruba peoples of Nigeria, Chasmanthera dependens is used primarily for pain relief, inflammation, fever, and malaria-associated febrile illness. Healers prepare decoctions from the stems and leaves, often combining the plant with other herbs in polyherbal formulations targeting these conditions. Its analgesic and anti-inflammatory applications are the most consistently documented across ethnic groups and geographic regions in West and Central Africa.
What are the main active compounds in Chasmanthera dependens?
The plant contains a complex alkaloid profile including quaternary protoberberines—jatrorrhizine, columbamine, pseudocolumbamine, magnoflorine, and palmatine—concentrated primarily in the stem, as well as tertiary aporphine alkaloids such as tetrahydropalmatine, glaucine, liriodenine, and nornuciferine in the leaves. The furanoditerpenoid epoxycolumbin has been isolated and shows antimicrobial potential. Leaf extracts also contain tannins, saponins, flavonoids, and phenolic compounds; however, no quantitative concentration data (e.g., mg/g) have been published for any of these constituents.
Are there human clinical trials on Chasmanthera dependens?
No human clinical trials have been conducted on Chasmanthera dependens for any indication as of current indexed literature. All available evidence is preclinical, derived from rodent analgesic and anti-inflammatory models (100–400 mg/kg oral doses) and in vitro cell-free assays measuring COX-2, TNF-α, and PGE-2 inhibition. The ingredient should be considered at the earliest stage of research translation, and therapeutic claims cannot be substantiated for human populations.
Is Climbing Blueflower safe to take as a supplement?
The safety of Chasmanthera dependens in humans is entirely unknown because no human safety studies, toxicology trials, or pharmacokinetic investigations have been published. Rodent studies at 100–400 mg/kg methanol extract reported no overt toxicity, but systematic toxicological characterization is lacking. Because the plant contains protoberberine alkaloids—a class known to inhibit drug-metabolizing enzymes like CYP3A4 in other species—caution is warranted especially for individuals taking prescription medications, and use during pregnancy or lactation cannot be considered safe without supporting data.
How does Chasmanthera dependens work as an anti-inflammatory?
Methanol leaf extracts of Chasmanthera dependens inhibit cyclooxygenase-2 (COX-2), suppressing prostaglandin E2 (PGE-2) synthesis and reducing peripheral inflammatory sensitization; they also downregulate the pro-inflammatory cytokine TNF-α, suggesting interference with NF-κB–driven gene transcription. The protoberberine alkaloids jatrorrhizine and palmatine are considered the principal bioactive contributors to this pathway modulation, based on their known pharmacology in structurally related Menispermaceae plants. These mechanisms are inferred from mediator inhibition data and rodent pharmacology; direct receptor-binding or gene-expression studies specific to Chasmanthera dependens have not been published.
Does Climbing Blueflower interact with nonsteroidal anti-inflammatory drugs (NSAIDs) like ibuprofen or diclofenac?
Since Chasmanthera dependens exhibits anti-inflammatory effects comparable to or exceeding diclofenac in polyherbal formulations through COX-2 inhibition, concurrent use with prescription or over-the-counter NSAIDs may potentiate effects and increase risk of gastrointestinal or cardiovascular side effects. Consultation with a healthcare provider before combining Climbing Blueflower with NSAIDs is recommended to avoid redundant mechanisms of action. No specific drug interaction studies have been published for this ingredient in humans.
What is the most effective form of Chasmanthera dependens—extract, powder, or whole leaf?
Methanol leaf extracts have demonstrated the strongest documented anti-inflammatory and analgesic activity in research, with efficacy linked to concentrated levels of protoberberine alkaloids (jatrorrhizine and palmatine). Most clinical and preclinical evidence supporting Climbing Blueflower's benefits derives from standardized extracts rather than whole leaf or powdered forms. The optimal bioavailable form for human supplementation has not been definitively established through comparative clinical trials.
Who is most likely to benefit from Climbing Blueflower supplementation based on current evidence?
Individuals seeking natural anti-inflammatory or analgesic support may benefit most, particularly those looking for alternatives to NSAIDs like diclofenac, though evidence is primarily from in vitro and animal models. People with inflammatory conditions or minor pain may be the intended population, but human efficacy data remains limited. Those with contraindications to NSAIDs should consult a healthcare provider before use, as the extent of safety and efficacy in vulnerable populations has not been established.
Explore the Full Encyclopedia
7,400+ ingredients researched, verified, and formulated for optimal synergy.
Browse IngredientsThese statements have not been evaluated by the Food and Drug Administration. This content is for informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease.
hermetica-encyclopedia-canary-zzqv9k4w climbing-blueflower-chasmanthera-dependens curated by Hermetica Superfoods at ingredients.hermeticasuperfoods.com and licensed CC BY-NC-SA 4.0 (non-commercial share-alike, attribution required)
